Zenas BioPharma, Inc.
Price Action
Technical Summary
WEAKENINGZenas BioPharma, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is moderate (RS Rating: 65), indicating performance broadly in line with the market. Earnings contraction of 83% provides fundamental context to the price action. However, price is extended 38% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $22.02 | +25.71% | ABOVE |
| 50 SMA | $20.11 | +37.62% | ABOVE |
| 100 SMA | $21.65 | +27.84% | ABOVE |
| 150 SMA | $23.95 | +15.58% | ABOVE |
| 200 SMA | $24.97 | +10.86% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ZBIO in an uptrend right now?
ZBIO has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is ZBIO overbought or oversold?
ZBIO's RSI (14) is 67. The stock is in neutral territory, neither overbought nor oversold.
Is ZBIO outperforming the market?
ZBIO has a Relative Strength (RS) Rating of 65 out of 99. ZBIO is performing about average compared to the market.
Where is ZBIO in its 52-week range?
ZBIO is trading at $27.68, which is 62% of its 52-week high ($44.60) and 51% above its 52-week low ($9.85).
How volatile is ZBIO?
ZBIO has a Beta of 1.06 and 52-week volatility of 112%. It's more volatile than the S&P 500 - expect bigger swings.